From the Desk of Evan Yu: What should I do with my new metastatic clear cell renal carcinoma patients?
For the past few years, most patients have received sunitinib1 or pazopanib2 for new metastatic clear cell renal carcinoma. Yet, the National Comprehensive Cancer Network (NCCN guidelines)3 also provide other preferred category 1 options in bevacizumab + interferon4 and temsirolimus5 specifically for those patients with poor prognostic features.
Evan Yu, MD
Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.
Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.
- Professor, Department of Medical Oncology, University of Washington School of Medicine
- Member, Fred Hutchinson Cancer Research Center
- Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.